Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC (TEDOVA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04713514
Recruitment Status : Not yet recruiting
First Posted : January 19, 2021
Last Update Posted : January 20, 2021
Sponsor:
Collaborators:
OSE Immunotherapeutics
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
ARCAGY/ GINECO GROUP

Brief Summary:

The proposed study is an international randomized phase II, multicenter, open-label, three arms trial to assess best supportive care (BSC) vs OSE2101 and vs OSE2101 + pembrolizumab as maintenance treatment for patients with platinum sensitive relapsed ovarian cancers, previously treated with 1 to 2 lines of chemotherapy, bevacizumab (if eligible) and a PARP inhibitor (if eligible).

Patients in Complete Response, Partial Response, or Stable Disease at the end of chemotherapy with at least 4 cycles of platinum based chemotherapy will be randomized in one of the three arms (randomization 1:1:2). They will receive one or the two study treatments or BSC until progression , or intolerance, or up to 2 years (from 1st study treatment dose).


Condition or disease Intervention/treatment Phase
Platinum-sensitive Ovarian Cancer Relapsed Ovarian Cancer Drug: OSE2101 Drug: Pembrolizumab 25 MG/ML [Keytruda] Phase 2

Detailed Description:

The only therapeutic option for ovarian cancer patients presenting with 1st or 2nd platinum sensitive relapse post- both bevacizumab and a PARPi is a platinum combination x 6 cycles followed by observation. There is no currently approved maintenance therapy in this setting. There is an urgent need for novel strategies for OC in 1st or 2nd relapse post bevacizumab and PARPi, in particular for novel maintenance strategies to prolong chemotherapy-free intervals.

One attractive strategy to turn OC from 'cold' tumors into a 'hot' tumor is via vaccination with tumor associated, or specific epitopes that have been modified to increase MHC and TCR binding.

OSE2101 is a multi-neoepitope vaccine covering relevant TAAs in OC, including p53 (mutated in 95% of high-grade OC). In addition, the combination of OSE2101with an ICI may most effectively harness anti-tumor immunity.

If novel IO approaches are proposed in OC, they should be investigated early in the disease setting when host immunity is still robust, and with low tumor burden (1st or 2nd platinum sensitive relapse and after 6 cycles of platinum chemotherapy).

The hypothesis being tested is that OSE2101 alone or in combination with Pembrolizumab as maintenance treatment in patients with ovarian cancer platinum-sensitive relapse could potentially bring benefit to subjects with high unmet medical need.

A total of 180 patients with HLA-A2 positive phenotype will be randomized using an Interactive Web Response System (IWRS) according to the following stratification factor:

• Best response to platinum therapy: SD vs PR/CR

In a 1:1:2 ration on the 3 study arms:

  • Arm A (n=45): Observation/best supportive care
  • Arm B (n=45): OSE2101: every 3 weeks until week 18, then every 6 weeks up to week 48, then every 12 weeks until disease progression, intolerance, patient withdrawal of consent or up to 2 years
  • Arm C (n=90): OSE2101 + Pembrolizumab: OSE2101 same schedule as arm B plus pembrolizumab IV every 6 weeks until disease progression, intolerance, patient withdrawal of consent or up to 2 years

Patient with phenotype HLA-A2 negative will be followed in a separate cohort to record treatment and outcomes.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized Phase II Study Comparing Neo-epitope Based Vaccine OSE2101 (TEDOPI®) With or Without Anti-PD1 (Pembrolizumab) Versus Best Supportive Care as Maintenance Treatment in Platinum-sensitive Recurrent Ovarian Cancer Patient With Controlled Disease After Platinum-based Chemotherapy
Estimated Study Start Date : March 2021
Estimated Primary Completion Date : March 2025
Estimated Study Completion Date : March 2025


Arm Intervention/treatment
No Intervention: Arm A : Best Supportive Care
Observational arm (Standard of care)
Experimental: Arm B : OSE2101

OSE2101 monotherapy - subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.

OSE2101 vaccine is an emulsion of peptides suspension in in Montanide® ISA 51 adjuvant and containing 0.5 mg/mL of each 10 synthetically manufactured peptides (5.0 mg/mL total peptide) in 1.5 mL of emulsion.

Drug: OSE2101
subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
Other Name: TEDOPI®

Experimental: Arm C : OSE2101 + Pembrolizumab
OSE2101 (subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years) + pembrolizumab (400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
Drug: OSE2101
subcutaneous injection on day 1, every 3 weeks for 7 doses then every 6 weeks up to week 48 and then every 12 weeks until intolerance, disease progression, or up to 2 years.
Other Name: TEDOPI®

Drug: Pembrolizumab 25 MG/ML [Keytruda]
400 mg IV infusion on day 1 every 6 weeks until intolerance, disease progression, or up to 2 years.
Other Names:
  • KEYTRUDA®
  • MK-3475




Primary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: from date to randomization to date of event, assessed up to 4 years ]
    Progression-free survival (PFS) is the time from randomization to progression measured radiologically using RECIST v1.1 guidelines as reported by the investigator or death, whatever the cause, whichever comes first. Patients alive and free of progression at the cut-off date will be censored at the last tumor assessment date


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: from date to randomization to date of event, assessed up to 4 years ]
    Objective response rate is defined using RECIST v1.1. Best overall response is defined as the best radiological response observed over the whole evaluation period before progression or subsequent anti-cancer treatment. Proportion of partial and complete responses over the treated population will be computed.

  2. Incidence of treatment emergent adverse events [ Time Frame: from date to randomization to date of study end, assessed up to 4 years ]
    Incidence of treatment emergent adverse events will be assessed based on NCI CTC-AE version 5.0 grade and according MedDRA terms (version 23.0)

  3. Time to subsequent first treatments (TTST-1) [ Time Frame: from date to randomization to date of event, assessed up to 4 years ]
    Time to subsequent treatment (TTST) is the time from randomization to initiation of a first subsequent treatment (including treatment change due to toxicity or investigator's decision). Deaths will be counted as events. Patients alive and not receiving a subsequent treatment will be censored at the last assessment date.

  4. Time to subsequent second treatments (TTST-2) [ Time Frame: from date to randomization to date of event, assessed up to 4 years ]
    Time to subsequent treatment (TTST) is the time from randomization to initiation of second subsequent treatment (including treatment change due to toxicity or investigator's decision). Deaths will be counted as events. Patients alive and not receiving a subsequent treatment will be censored at the last assessment date.

  5. Overall Survival (OS) [ Time Frame: from date to randomization to death from any cause, assessed up to 4 years ]
    Overall Survival (OS) is defined as time from randomization to the date of death, whatever the cause. Patients alive at the cut-of date will be censored at the last date they are known to be alive



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed and dated informed consent document for the study, willing and able to comply with protocol requirements, including:

    1. HLA-A2 phenotype determination by genetic test (blood)
    2. participation in translational research in HLA-A2 positive
    3. authorization for long term follow up if HLA-A2 negative
  2. Histologically or cytologically proven non-mucinous epithelial ovarian cancer
  3. Positive HLA-A2 phenotype
  4. Age ≥ 18 years
  5. ECOG Performance Status (PS) 0-1
  6. First or second clinical or radiological relapse of a platine sensitive ovarian cancer in complete response, partial response or stable disease according to RECIST 1.1 at the end of a platinum based chemotherapy. Patient must have received at least 4 cycles of platinum during this chemotherapy
  7. Previously treated with a PARP inhibitor or not eligible to PARPi (i.e ineligibility due to not complete or partial response to chemotherapy)
  8. Prior therapy with bevacizumab or with contra-indication to bevacizumab (i.e arterial thromboembolic events, history of intestinal perforation, any other contra-indications according to the SmPC)
  9. Randomization must be within 8 weeks of last dose of platinum
  10. Adequate organ function

    • Adequate marrow function

      • White blood cell (WBC) ≥ 3000/ mm3
      • Neutrophils ≥ 1500/ mm3
      • Platelets ≥ 100 × 103/mm3 (in the absence of transfusion within 2 weeks from before randomization)
      • Haemoglobin ≥ 9 g/dL (in the absence of transfusion within 2 weeks from before randomization)
    • Adequate other organ functions

      • ALT and AST ≤ 2.5 × ULN, unless liver metastases are presents in which case they must be ≤ 5.0 × ULN
      • Total bilirubin ≤ 1.5× ULN (except Gilbert Syndrome: < 3.0 mg/dL)
      • Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL/min (measured using the Cockcroft-Gault formula below):

    Female CrCl = (140 - age in years) × weight in kg × 0.85 72 × serum creatinine in mg/dL

  11. Archival or fresh (if possible) tumor tissue must be available for evaluating relevant biomarkers. Formalin-fixed paraffin-embedded [FFPE] block preferred, or a minimum of 30 unstained FFPE slides of one archived block is required.
  12. Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to treatment allocation, and have to use of highly effective contraception during the treatment period and for at least 120 days after the last dose of study treatment
  13. Stated willingness to comply with all study procedures and availability for the duration of the study
  14. For countries where this will apply to : a subject will be eligible for randomization in this study only if either affiliated to, or a beneficiary of, a social security category

Exclusion Criteria:

  1. Prior treatment with any immune checkpoint inhibitor, including anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody
  2. Patient with contra-indications to immune therapies
  3. Ongoing immunotherapy (checkpoint inhibition, antigen immunotherapy that would be scheduled to continue concomitantly to the study)
  4. Use of any of the following immunomodulatory agents within 30 days prior to the first dose of study drug:

    • Systemic corticosteroids (at dose higher than 10 mg/day equivalent prednisone); if systemic corticoid use, corticoid must be stopped at least 7 days before study treatment start
    • Interferons
    • Interleukins
    • Live vaccine Note: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster, yellow fever, rabies, BCG, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed as other killed vaccines, if done at least 2 weeks prior the first dose of study drug; however, intranasal influenza vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
  5. Prior cancer vaccine therapy
  6. Patient eligible for cytoreductive surgery at the time of inclusion
  7. Prior radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
  8. Patient with active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment and is allowed.
  9. History of serious adverse reactions, including anaphylaxis and related symptoms such as hives and respiratory difficulty following administration of any vaccines, or a history of hypersensitivity, specifically to any components of study vaccine
  10. Prior history of other malignancies other than study disease (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or other in situ cancer considered as cured) unless the patient has been free of the disease for at least 5 years.
  11. Immune-deficient status (patients with HIV, immunosuppressive treatment, haematological malignancies, and previous organ transplantation)
  12. History of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease that requires steroids.
  13. History of any chronic hepatitis as evidenced by:

    • Positive test for hepatitis B surface antigen
    • Positive test for qualitative hepatitis C viral load (by polymerase chain reaction [PCR]) Note: Subjects with positive hepatitis C antibody and negative quantitative hepatitis C by PCR are eligible. History of resolved hepatitis A virus infection is not an exclusion criterion
  14. Uncontrolled or significant cardiovascular disease including, but not limited to, any of the following:

    • Myocardial infarction or stroke/transient ischemic attack within the past 6 months
    • Uncontrolled angina within the past 3 months
    • History of other clinically significant heart disease (eg, cardiomyopathy, congestive heart failure with New York Heart Association functional classification III-IV, pericarditis, significant pericardial effusion, or myocarditis)
    • Any history of clinically significant arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
    • QT interval corrected for heart rate using Fridericia's formula (QTcF) prolongation > 480 msec
    • Cardiovascular disease-related requirement for daily supplemental oxygen therapy
  15. Subjects with known or suspected CNS metastases, untreated CNS metastases, are excluded. However, subjects with controlled brain metastases will be allowed to enroll. Controlled brain metastases are defined as no radiographic progression for at least 4 weeks following radiation and/or surgical treatment (or 4 weeks of observation if no intervention is clinically indicated), and off of steroids for at least 2 weeks, and no new or progressive neurological signs and symptoms.
  16. Any major surgery within 4 weeks of study drug administration. Subjects must have recovered from the effects of major surgery or significant traumatic injury at least 14 days before date of randomization.
  17. Patients who has severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients (refer to the IB for a list of excipients).
  18. Patients who has an active infection requiring systemic therapy.
  19. Any acute medical condition that in the opinion of the investigator may obscure the ability to observe the safety or activity of the study vaccine treatment
  20. Any mental or psychiatric condition that, in the opinion of the investigator, is likely to compromise the ability to adhere to the protocol schedule
  21. Life expectancy of less than 12 weeks
  22. Pregnant or breastfeeding women
  23. Concurrent participation in any other investigational study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04713514


Contacts
Layout table for location contacts
Contact: Sophie Brutto +33 1 84 85 20 20 tedova-study@arcagy.org

Locations
Show Show 26 study locations
Sponsors and Collaborators
ARCAGY/ GINECO GROUP
OSE Immunotherapeutics
Merck Sharp & Dohme Corp.
Investigators
Layout table for investigator information
Principal Investigator: Alexandra LEARY, MD,PHD GINECO - Gustave Roussy
Layout table for additonal information
Responsible Party: ARCAGY/ GINECO GROUP
ClinicalTrials.gov Identifier: NCT04713514    
Other Study ID Numbers: GINECO-OV244b
2020-004364-25 ( EudraCT Number )
ENGOT-ov58 ( Other Identifier: ENGOT )
First Posted: January 19, 2021    Key Record Dates
Last Update Posted: January 20, 2021
Last Verified: January 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by ARCAGY/ GINECO GROUP:
Maintenance therapy
Immunotherapy
Cancer vaccine
Cold tumor
Relapse
Pembrolizumab
TEDOPI
Additional relevant MeSH terms:
Layout table for MeSH terms
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Hypersensitivity
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Immune System Diseases
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents